Log In
Wednesday 26th October 2016

Leukaemia treatment in heart scare

2nd August 2006

15032006_artery1.jpgA leukaemia treatment hailed as the next generation of cancer care, has been linked to heart failure.

About 2,500 people in Britain take Glivec, known generically as imatinib, which has transformed the treatment of chronic myeloid leukaemia (CML) since its launch in 2001.

Around nine out of 10 patients who take it are still alive after five years. Despite the research by American scientists claiming it can be dangerous to the heart in journal Nature Medicine, they advise patients continue treatment.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2016